炒美股，就跟着马斯克和川普，就完事了！🧐 太空科技公司 推荐价 现价 #RKLB 57 👉 87 #ASTS 79 👉 111 #PL 12.94 👉 28 #FLY 21.3 👉 29.35 #RDW 7.48 👉 14.2

说明一下：我做这期视频不是让大家现在立马去买$RKLB，最近股价涨的太猛了，从写文案到做成视频，股价就涨了40%+。 长期标的，等合理价格在上车，切勿fomo

如果我开头放这张图 流量会不会好很多？

Rocketlab火箭实验室( $RKLB )是我从去年开始关注买入，并非常看好的一家公司。 在商业航天的道路上，不只有Space X、蓝色起源这种资金雄厚的超级巨头，Rocketlab这种一步一个脚印，从小火箭切入细分市场，到如今进军可回收中型火箭，每一步都坚韧和踏实。 从2024年7月份至今，短短一年半股价已经飙涨超过20倍；而未来随着Space X的上市和商业航天热潮的推动，公司股价仍然有发展空间。 本期视频将聚焦Rocketlab的发展历史，来解码火箭实验室成功背后的独特基因。 本期视频将是你了解Rocketlab最不容错过的内容，点赞+转发+评论本条视频推文，有机会抽奖获得价值130 USD的中子号火箭模型一个（或等值u）。

去年12月太空经济板块可以说是中美共振了，美股太空经济几家主力基本上都翻倍了。心头好小火箭RKLB表现也很亮眼。过去一个月对RKLB来说绝对是业务上的超级月：1、拿到了美国太空发展局超过8亿美金，18颗卫星订单。这些卫星还配备卫星配备Rocket Lab的StarLite防护传感器（可防御定向能量威胁），并扩展到向其他承包商供应传感器； 2、同时还拿到加拿大、日本航天机构的新合同； 3、25年全年完成21次Electron火箭发射，年度100%任务成功率（全球小型火箭最活跃）。包括12月为iQPS发射SAR卫星（这是iQPS的第7颗，未来计划5次更多）。 4、中性火箭中子星Neutron进展：首飞仍目标2026年中（Q1运抵Wallops发射台，资格测试中）。Hungry Hippo可重复使用整流罩已完成资格测试； 拿到太空发展局的合同意味着RKLB正式跻身为最大的国防太空承包商之一；如果26年中中子星发射成功，意味着RKLB成功从小型火箭发射升级到中性火箭发射。 美股太空经济股票，有好几只在链上美股平台@MSX_CN 上都能交易，可以关注起来https://t.co/SwrikLq3oN

时代的裹挟，也是每个人成长之路必须面对的周期性命题，尘封的历史画卷也在徐徐打开 $RKLB Planet Labs $KTOS $ONDS Kraken Robotics

中美太空资源争夺白热化，这两天一条新闻值得关注，中国在去年12月正式向国际电信联盟（ITU）提交20.3万颗低轨卫星申报，涵盖14个星座，仅两大核心星座CTC-1与CTC-2就各达9.6万余颗，规模相当于美国星链申报总量的近5倍。 本次申报主体包括无线电创新院、中国移动、垣信卫星等机构。无线电创新院于2025年12月29日提交两个近10万颗卫星的巨型星座申请，并于次日（12月30日）完成河北雄安新区注册登记，成为中国无线电管理技术领域首家新型研发机构。 战略意图： 国际电信联盟（ITU）是太空的“规则制定者”，核心规矩就一条：“先申报、先发射、先占用”。低轨（距离地球300-2000公里）是太空里的“黄金地段”，信号快、延迟低，未来6G通信、军事指挥都离不开它，就像城市里的核心停车位，占一个少一个。 老马的星链动手更早：截至2025年底，在轨卫星快到1万颗，占了全球低轨卫星的2/3，还申报了4.2万颗，把好位置占得差不多了 中国此举旨在抢占低轨卫星频轨资源，应对国际竞争。目前全球低轨资源遵循“先占先得”规则，中国通过大规模申报锁定资源。 当然ITU审批通过后并不是一劳永逸，根据ITU规则，申报单位需在7年内发射首颗卫星，第9年完成10%部署，第12年完成50%部署，第14年完成全部部署。 中国现在大规模申报意味着从卫星制造到火箭发射，全产业链都已准备就绪，这是有明确路线图的国家工程，绝不是虚张声势。 所以说太空资源争夺已是白热化

小火箭🚀

2026年值得关注的顶级增长主题 • 加密货币 | $HOOD $COIN $BMNR • 量子 | $IONQ $RGTI $QBTS • 机器人 | $TSLA $SYM $ISRG $RR • 核能 | $OKLO $LEU $GEV $UUUU • AI 公用设施 | $CRWV $NBIS $IREN $CIFR • AI 芯片 | $NVDA $TSM $ASML $AMD • 电网与电力 | $CEG $NEE $VST $EOSE • 无人机 | $ONDS $UMAC $DPRO $AVAV • AI 数据平台 | $PLTR $SNOW $MDB • AI 安全 | $CRWD $ZS $PANW $RBRK • 太空经济 | $RKLB $ASTS $PL $RDW • AI 网络 | $AVGO $ALAB $MRVL $CRDO • AI 云 | $MSFT $AMZN $GOOGL $DOCN $ORCL cc @BTCBruce1

When $RKLB hits $80+

$RKLB $38C 07/18/2025 was filled at $2.12, now trading at $10.00 — that’s a 371% return. They’re sitting on millions in just One Week. Check out that opening Flow on 7/7

$RKLB over +70% in 3 weeks since I posted insane gains for a stock in such a short period of time on size sold all of my position here

$RKLB +50% this is some crazy numbers for the stock market on good size. I keep cashing out more and more from crypto and putting into stocks FYI, stocks are so stupid easy it's enjoyable

🛰️ $RKLB $38C 07/18/2025 calls alerted below caught a +30% intraday move today via UW alert

trading stocks is so easy mode it's actually retarded I'm not joking even a 5 year old could make money in this market

Missing Pengu and few other bangers But this is ALT season. And has been going on for four years while random morons on CT are waiting for some 2017 VC scam coin to pump in a “alt season” This is literally why Weekly Wizdom has killed it last 2 years

$RKLB looks good for $44

Earnings Summary & Key Updates 🔸 Monster Beverage ( $MNST) Q4 EPS: $0.38 (vs. est. $0.40); Revenue up 4.7% YoY to $1.81B (vs. est. $1.8B). Gross profit margin improved to 55.5% (Non-GAAP). Operating income up 7.9% to $517.9M (Non-GAAP). 🔸 Tesla ( $TSLA) applied for a permit in California linked to chauffeur services, a step toward regulatory approval for its planned robotaxi service. 🔸 Array Technologies ( $ARRY) – Q4 adj. EPS: $0.16 (vs. est. $0.17), adj. EBITDA: $45.2M (vs. est. $47.6M), revenue: $275.2M (vs. est. $268.5M), gross margin: 28.5%. Q1 revenue guidance: $260M-$270M (vs. est. $292.17M), FY revenue: $1.05B-$1.15B (vs. est. $1.127B). 🔸 Bloom Energy ( $BE) – Q4 adj. EPS: $0.43 (vs. est. $0.30), revenue: $572.4M (vs. est. $508.28M), gross margin: 38.3%, op. margin: 18.3%. FY revenue guidance: $1.65B-$1.85B (vs. est. $1.671B), adj. op. income: $135M-$165M (vs. est. $126.44M). 🔸 EOG Resources ( $EOG) – Q4 adj. EPS: $2.74 (vs. est. $2.57), revenue: $5.59B (vs. est. $5.95B). Oil & gas volumes and costs outperformed guidance. Announced $6.2B 2025 capital plan to grow oil production 3% and total production 6%. Entered a strategic agreement with Bapco Energies in Bahrain. 🔸 Sunrun ( $RUN) – Q4 revenue: $518.5M (vs. est. $537.9M). Installed 392 MWh of storage, up 78% YoY, exceeding guidance. Storage attachment rate: 62%. Q1 cash generation expected at $40M-$50M. 🔸 Talen Energy ( $TLN) – FY adj. EBITDA: $770M, adj. free cash flow: $283M, exceeding 2024 guidance midpoints. Reaffirmed 2025 guidance; 2026 outlook unchanged. 🔸 Tidewater ( $TDW) – Q4 revenue: $345.1M (vs. est. $340.1M), adj. EBITDA: $138.4M (in line with estimates). FY revenue guidance: $1.32B-$1.38B (vs. est. $1.44B), gross margin: 48%-50% (vs. est. 50.1%). 🔸 CubeSmart ( $CUBE) – Q4 AFFO/share: $0.68 (in line), adj. EPS: $0.45 (vs. est. $0.46), revenue: $231.4M (vs. est. $266.4M). FY AFFO/share guidance: $2.50-$2.59 (vs. est. $2.68), EPS: $1.40-$1.49 (vs. est. $1.76). 🔸 Green Dot ( $GDOT) – Q4 EPS: $0.40 (vs. est. $0.35), revenue: $455M (vs. est. $421.9M). FY25 EPS guidance: $1.05-$1.20 (vs. est. $1.50), adj. EBITDA: $145M-$155M. Expects embedded finance and money movement to drive 2025 growth. 🔸 Redfin ( $RDFN) – Q4 EPS loss: (-$0.29) (vs. est. -$0.23), revenue up 12% YoY to $244.3M (vs. est. $242.5M). Q1 revenue guidance: $214M-$225M (vs. est. $242.8M), Q1 net loss expected at ($94M-$83M). Q4 adj. EBITDA: $2.9M. 🔸 Rocket Companies ( $RKT) – Q4 adj. EPS: $0.04 (vs. est. $0.03), total revenue: $1.76B, adj. revenue: $1.2B (high end of guidance). Q1 revenue guidance: $1.17B-$1.325B. 🔸 Acadia Healthcare ( $ACHC) – Q4 adj. EPS: $0.64 (vs. est. $0.71), adj. EBITDA: $153.1M (vs. est. $171.4M), revenue: $774.2M (vs. est. $779M). FY revenue guidance: $3.3B-$3.4B (vs. est. $3.441B), adj. EBITDA: $675M-$725M (vs. est. $747.9M), adj. EPS: $2.50-$2.80 (vs. est. $3.35). 🔸 Iovance Biotherapeutics ( $IOVA) – Q4 EPS loss: (-$0.26) (vs. est. -$0.27), revenue: $73.7M (vs. est. $72.2M). Reaffirms FY25 total product revenue guidance of $450M-$475M. Amtagvi total revenue: $73.7M in Q4, $164.1M in FY24. 🔸 Natera ( $NTRA) – Q4 EPS: (-$0.41) (vs. est. -$0.42), revenue: $476.1M (vs. est. $428.6M). FY revenue guidance: $1.87B-$1.95B (vs. est. $1.819B), gross margin: 60%-64%. 🔸 Pacira BioSciences ( $PCRX) – Q4 EPS: $0.96 (vs. est. $0.83), revenue: $187.3M (vs. est. $185.4M). FY25 revenue guidance: $725M-$765M (vs. est. $747.6M), gross margin: 76%-78%, R&D expense: $90M-$105M, SG&A expense: $290M-$320M. 🔸 Progyny ( $PGNY) – Q4 adj. EPS: $0.42 (vs. est. $0.10), adj. EBITDA: $47.5M (vs. est. $41.8M), revenue: $298.4M (vs. est. $276.7M). Q1 revenue guidance: $300M-$318M (vs. est. $280.3M), FY revenue: $1.175B-$1.225B (vs. est. $1.159B), adj. EPS: $1.52-$1.62 (vs. est. $0.60). 🔸 RadNet ( $RDNT) – Q4 adj. EPS: $0.22 (vs. est. $0.20), adj. EBITDA: $75M (vs. est. $74.8M), revenue: $477.1M (vs. est. $461.8M). FY revenue guidance: $1.825B-$1.875B (vs. est. $1.979B), adj. EBITDA: $265M-$273M (vs. est. $309.3M), FCF: $70M-$80M. 🔸 Solventum ( $SOLV) – Q4 adj. EPS: $1.41 (vs. est. $1.32), revenue: $2.07B (vs. est. $2.05B). FY adj. EPS guidance: $5.45-$5.65 (vs. est. $5.49). 🔸 TransMedics Group ( $TMDX) – Q4 EPS: $0.19 (vs. est. $0.16), revenue: $121.6M (vs. est. $110.3M), gross margin: 59%. FY revenue guidance: $530M-$552M (vs. est. $528.6M). 🔸 Boeing ( $BA) & Safran – Assessing impact of a fire at Pennsylvania's SPS Technologies factory, seeking alternative suppliers. GE Aerospace (GE) taking steps to minimize disruption. 🔸 Archer Aviation ( $ACHR) – Q4 adj. EBITDA: -$94.8M, operating expenses up 16% YoY to $124.2M, net loss: -$198.1M (+82% YoY). Q1 adj. EBITDA loss guidance: -$95M to -$110M. 🔸 MasTec ( $MTZ) – Q4 EPS: $1.44 (vs. est. $1.26), revenue: $3.4B (+3.8% YoY, vs. est. $3.32B). Q1 EPS guidance: $0.34 (vs. est. $0.39). 2025 outlook: revenue $13.45B (+9% YoY), GAAP net income: $327M-$366M, adj. EBITDA: $1.10B-$1.15B. 🔸 Mosaic ( $MOS) – Q4 adj. EPS: $0.45 (vs. est. $0.57), revenue: $2.8B (vs. est. $2.92B). Missed estimates due to lower potash prices and sales. Q4 potash sales volume: 2.2M tonnes (-15% YoY), avg. price: $199/tonne (-18%). Potash revenue: $600M (-25%), adj. core profit: $95M (-24%). 🔸 Rocket Lab USA ( $RKLB) – Q4 adj. EBITDA: -$23.2M (vs. est. -$29.1M), revenue: $84M (vs. est. $130.6M). Q1 revenue guidance: $117M-$123M (vs. est. $135.7M), adj. gross margin: 30%-32%, adj. EBITDA: -$35M. 🔸 Autodesk ( $ADSK) – Q4 adj. EPS: $2.29 (vs. est. $2.14), revenue: $1.6B (vs. est. $1.632B), adj. EBIT margin: 37%. Q1 guidance: revenue $1.6B-$1.61B (vs. est. $1.598B), EPS $2.14-$2.17 (vs. est. $2.08). FY guidance: revenue $6.895B-$6.965B, adj. op margin 36%-37%, EPS $9.34-$9.67 (vs. est. $9.24). 🔸 Dell ( $DELL) – Q4 adj. EPS: $2.68 (vs. est. $2.52), revenue: $23.9B (vs. est. $24.57B). Q1 guidance: EPS $1.65 (vs. est. $1.83), revenue $22.5B-$23.5B (vs. est. $23.72B). FY26 midpoint in line with consensus. Announced $10B stock buyback and 18% dividend increase to $2.10. 🔸 DoubleVerify ( $DV) – Q4 adj. EBITDA: $73.8M (vs. est. $76.48M), revenue: $190.6M (vs. est. $196.9M). Q1 guidance: revenue $151M-$155M (vs. est. $157.5M). FY revenue expected to grow ~10% (vs. est. 12.59%). 🔸 Duolingo ( $DUOL) – Q4 EPS: $0.28 (vs. est. $0.48), revenue: $209.6M (vs. est. $205.4M), paid subs: 9.5M, DAU: 40.5M, MAU: 116.7M. Q1 guidance: revenue $220.5M-$223.5M (vs. est. $221.07M). FY guidance: revenue $962.5M-$978.5M (vs. est. $965.88M). 🔸 Elastic ( $ESTC) – Shares surged on strong Q3 results: adj. EPS $0.63 (vs. est. $0.47), adj. op income $64M (vs. est. $55.4M), revenue $382.5M (vs. est. $368.7M). Q4 guidance: revenue $379M-$381M (vs. est. $374.2M), adj. op margin ~13.5%, adj. EPS $0.36-$0.37 (vs. est. $0.31). 🔸 HP ( $HPQ) – Q1 adj. EPS: $0.74 (in line), revenue: $13.5B (vs. est. $13.36B). Growth driven by strong personal systems segment: revenue up 5% to $9.2B, commercial PC revenue up 10%. Q2 guidance: EPS $0.75-$0.85 (vs. est. $0.86). FY EPS: $3.45-$3.75 (vs. est. $3.59). 🔸 iHeartMedia ( $IHRT) – Q4 adj. EBITDA: $246M (vs. est. $291.3M), revenue: $1.118B (vs. est. $1.166B). Q1 guidance: adj. EBITDA $100M-$110M (vs. est. $120.25M). 🔸 NetApp ( $NTAP) – Q3 EPS: $1.91 (in line), revenue: $1.64B (vs. est. $1.7B). Q4 guidance below midpoint. FY25 guidance: EPS $7.17-$7.27 (vs. est. $7.33), revenue $6.49B-$6.64B (vs. est. $6.67B). 🔸 SoundHound AI ( $SOUN) – Q4 adj. EPS: -$0.05 (vs. est. -$0.10), revenue: $34.5M (vs. est. $33.69M). FY guidance: revenue $157M-$177M (vs. est. $165.26M).

RECAP • $CAVA: Q3 EPS $0.15, above expectations of $0.11; sales up 39% to $243.8M; FY guidance for restaurant comp sales at 12.5%, up from 8.5-9.5%, and EBITDA at $123M. Plans to increase restaurant openings and margins. • $FLUT: Q3 adjusted EBITDA up 74% to $450M; revenue up 27% to $3.25B; raised full-year forecasts for EBITDA and revenue, expecting 35% profit increase. • $CART: Q3 EPS $0.42 vs. $0.22 est.; revenue $852M vs. $844M est.; Q4 EBITDA guidance $230M-$240M, below estimate; increased buyback program by $250M. • $LNW: Q3 net income $64M, less than $100.7M expected; revenue $817M, slightly below $821.21M; continues double-digit revenue growth. • $RIVN: Formed JV with Volkswagen for tech development, with VW investing up to $5.8B by 2027. • $SAVE: Shares fell -60% due to bankruptcy filing rumors, currently negotiating with creditors. • $TSLA: Recalling 2,431 Cybertrucks due to potential power loss issues, marking the sixth recall this year. • $MODG: Q3 EPS loss at -$0.02, better than -$0.16 expected; revenue $1.01B, above $983M forecast; adjusted full-year revenue and EBITDA guidance downwards. • $OXY: Q3 adj EPS $1.00, above $0.74 expected; production rose 15.7% to 1.41 Mboepd due to CrownRock acquisition, despite lower prices; Q4 production expected at 1.43-1.47 Mboepd. • $RKLB: Q3 EPS ($0.10) vs. ($0.11) est., with revenues at $104.8M vs. $102.3M est.; Q4 revenue guidance $125-135M, with a new multi-launch deal for Neutron. • $DHT: Q3 EPS $0.22, topping $0.20 estimate; adjusted EBITDA $70.4M vs. $66.4M expected, on slightly lower than expected adjusted revenues of $92.64M. • $AB): Reported a 2% drop in AUM to $793B in October 2024 from $806B due to market downturn, with no net inflows or outflows. • $MARA: Q3 revenue increased by 34% to $131.6M, missing the forecast of $137.5M. • $PAY: Q3 EPS was $0.15 compared to $0.09 expected; revenue hit $231.6M against $190.6M estimated. They foresee Q4 revenue at $215M-$220M and FY24 at $829M-$834M, both above consensus. • $RKT: Q3 adjusted EPS met estimates at $0.08; adjusted EBITDA was $286M, above the $272.33M expected, with revenues at $1.323B, beating the forecast. They anticipate a drop in Q4 revenue to $1.05-1.2B. • $WULF: Q3 adjusted EBITDA was $6M, below the $11.2M prediction, with revenues at $27.1M, not meeting the $34.28M estimate. • $AMGN: Clarified no link between MariTide use and bone density changes, despite earlier reports of potential loss. The company remains confident in the drug's future. • $ICUI: Q3 adjusted EPS $1.59 vs $1.25 expected; revenue $589.131M vs $574.7M forecast, with a gross margin of 34.8%. FY guidance raised for EPS and EBITDA. • $NTRA: Q3 EPS ($0.26) vs ($0.57) expected, revenue $439.8M vs $361.45M; FY revenue guidance set at $1.61-1.64B, above consensus. • $PGNY: Q3 EPS $0.11, below $0.13 expected; revenue $286.625M vs $296.88M; full-year revenue and EBITDA guidance below market expectations. • $SGMO: Q3 EPS $0.04, better than ($0.03) expected; revenue $49.41M vs $17.94M forecast. Adjusted annual operating expenses expected to be $125-145M. • $SYRS: Shares dropped -80% after the SELECT-MDS-1 trial for tamibarotene failed to meet its primary endpoint, leading to discontinuation of the study. • $DOX: Q4 adjusted EPS $1.70, matching expectations, with revenue at $1.264B, slightly above the $1.263B estimate. • $PLUS: Q2 adjusted EPS $1.36, below $1.39 expected; revenue $515.2M vs $576.5M forecast. Full-year sales guidance unchanged, but adjusted EBITDA expected at $195-205M. • $IAS: Q3 EPS $0.10 vs $0.07 expected, with revenue at $133.528M and a gross margin of 80%. Q4 revenue and EBITDA guidance were both below expectations. • $SOUN: Q3 adjusted EPS ($0.04) vs ($0.07) expected; revenue $25.1M, above $23.02M estimate. Set FY24 and FY25 revenue targets. • $SWKS: Q4 adjusted EPS $1.55 vs $1.52, revenue $1.025B, nearly matching estimates. Q1 guidance for revenue and EPS below expectations. • $SPOT: Q3 revenue growth of 19% to €3.99B missed the €4.02B estimate; profit margin improved. Q4 revenue guidance below expectations but operating income and MAUs on target. • $SMCI: Announced delay in filing Q3 2024 quarterly report due to ongoing issues with the annual report. • $ZI: Q3 adjusted EPS $0.28, surpassing the $0.22 estimate; revenue $303.6M vs $299.38M. Q4 revenue guidance in line with estimates, but EPS slightly below consensus.

collateral: $SOL stocks: $COIN, $HOOD, $GLXY, $RKLB memes: $WIF, $MOG, $MEW, $MOTHER, $MICHI, $SCF altcoins: go do the homework perps: @HyperliquidX retirement: 2027